Tech Company Financing Transactions
BioCorteX Funding Round
Sofinnova Partners and Hoxton Ventures participated in a $5 million Seed funding round for BioCorteX. The round closed on 3/31/2023.
Transaction Overview
Company Name
Announced On
3/31/2023
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Seed
Investors
Sofinnova Partners (Lead Investor) (Edward Kliphuis)
Hoxton Ventures (Hussein Kanji)
Proceeds Purpose
The company intends to use the funds to further develop its platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
15-19 Bloomsbury Way
London England, WC1A 2TH
UK
London England, WC1A 2TH
UK
Phone
Undisclosed
Website
Email Address
Overview
BioCorteX will change this by leveraging the relationship between bacteria and medications We are developing the world's first clinically validated, knowledge-driven, human-microbiome platform that we will use to develop our own therapeutic pipeline. BioCorteX is a 'techbio' that applies deep technology to deliver effective therapeutics by leveraging the synergy between health and bacteria, viruses, and fungi. Our key product, CarbonMirror� uses deep tech and AI to simulate how the colossal number of microbiota interact with therapeutics, de-risking (pre-)clinical trials and replacing uncertainty with confidence for the patient.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nikhil Sharma
Browse more venture capital transactions:
Prev: 3/31/2023: Inven venture capital transaction
Next: 3/31/2023: Dunzo venture capital transaction
Share this article
News on VC Transactions
We do our best to record all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs